Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.

CONTEXT Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke. OBJECTIVE To estimate the risk of hemorrhagic stroke associated with aspirin treatment. DATA SOURCES Studies were retrieved using MEDLINE (search terms, aspirin, cerebrovascular disorders, and stroke), bibliographies of the articles retrieved, and the authors' reference files. STUDY SELECTION All trials published in English-language journals before July 1997 in which participants were randomized to aspirin or a control treatment for at least 1 month and in which the incidence of stroke subtype was reported. DATA EXTRACTION Information on country of origin, sample size, duration, study design, aspirin dosage, participant characteristics, and outcomes was abstracted independently by 2 authors who used a standardized protocol. DATA SYNTHESIS Data from 16 trials with 55462 participants and 108 hemorrhagic stroke cases were analyzed. The mean dosage of aspirin was 273 mg/d and mean duration of treatment was 37 months. Aspirin use was associated with an absolute risk reduction in myocardial infarction of 137 events per 10000 persons (95% confidence interval [CI], 107-167; P<.001) and in ischemic stroke, a reduction of 39 events per 10000 persons (95% CI, 17-61; P<.001). However, aspirin treatment was also associated with an absolute risk increase in hemorrhagic stroke of 12 events per 10000 persons (95% CI, 5-20; P<.001). This risk did not differ by participant or study design characteristics. CONCLUSIONS These results indicate that aspirin therapy increases the risk of hemorrhagic stroke. However, the overall benefit of aspirin use on myocardial infarction and ischemic stroke may outweigh its adverse effects on risk of hemorrhagic stroke in most populations.

[1]  Y. Tokuda,et al.  Aspirin and risk of hemorrhagic stroke. , 1999, JAMA.

[2]  Coumadin Aspirin Reinfarction Study Investigators.  Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.

[3]  R. Lin,et al.  Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. , 1997, Thrombosis research.

[4]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[5]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[6]  S. Pocock,et al.  A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial , 1996, BMJ.

[7]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[8]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[9]  P. Metcalf,et al.  Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. , 1996, American heart journal.

[10]  I. Puddey.  Low serum cholesterol and the risk of cerebral haemorrhage. , 1996, Atherosclerosis.

[11]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[12]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[13]  Zheng-lai Wu,et al.  Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. , 1995, Stroke.

[14]  M. Fujishima,et al.  A Randomized Trial of E5510 versus Aspirin in Patients with Transient Ischemic Attacks , 1995, Angiology.

[15]  M. Abrahamowicz,et al.  Lack of Effect of Aspirin in Asymptomatic Patients with Carotid Bruits and Substantial Carotid Narrowing , 1995, Annals of Internal Medicine.

[16]  C. Patrono.  Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.

[17]  L. Wilkins.  Randomized Trial of Ridogrel, a Combined Thromboxane A2 Synthase Inhibitor and Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist, Versus Aspirin as Adjunct to Thrombolysis in Patients With Acute Myocardial Infarction: The Ridogrel Versus Aspirin Patency Trial (RAPT) , 1994, Circulation.

[18]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[19]  Joseph L. Fleiss,et al.  Measures of effect size for categorical data. , 1994 .

[20]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[21]  R. Takolander,et al.  Does Low‐Dose Acetylsalicylic Acid Prevent Stroke After Carotid Surgery?: A Double‐blind, Placebo‐Controlled Randomized Trial , 1993, Stroke.

[22]  J. McNeil,et al.  Adverse effects of low‐dose aspirin in a healthy elderly population , 1993, Clinical pharmacology and therapeutics.

[23]  R. Carleton,et al.  Prevalence and Descriptors of Aspirin Use as an Antiplatelet Agent in Two New England Communities , 1993, The Annals of pharmacotherapy.

[24]  H. Hecker,et al.  Dose‐Dependent Effect of Aspirin on Carotid Atherosclerosis , 1993, Circulation.

[25]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[26]  N. Edvardsson,et al.  Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris , 1992, The Lancet.

[27]  D. Singer,et al.  The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. , 1992, American heart journal.

[28]  L. Hillis,et al.  The use of aspirin in ischemic heart disease. , 1992, The New England journal of medicine.

[29]  M. Laakso,et al.  European Stroke Prevention Study: Effectiveness of Antiplatelet Therapy in Diabetic Patients in Secondary Prevention of Stroke , 1992, Stroke.

[30]  C Warlow,et al.  The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[31]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.

[32]  A. Levy,et al.  Aspirin and hemorrhagic stroke. , 1991, Stroke.

[33]  S D Walter,et al.  A comparison of several point estimators of the odds ratio in a single 2 x 2 contingency table. , 1991, Biometrics.

[34]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[35]  Y. C. Chen,et al.  Secondary prevention of ischemic stroke with low dose acetylsalicylic acid. , 1990, Journal of the Formosan Medical Association = Taiwan yi zhi.

[36]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[37]  H. A. Kahn,et al.  Statistical Methods in Epidemiology , 1989 .

[38]  R. L. Rogers,et al.  Randomized Clinical Trial of Daily Aspirin Therapy in Multi‐Infarct Dementia , 1989, Journal of the American Geriatrics Society.

[39]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[40]  P. Sørensen,et al.  Danish very-low-dose aspirin after carotid endarterectomy trial. , 1988, Stroke.

[41]  A. Dávalos,et al.  Low‐dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks , 1987, Acta neurologica Scandinavica.

[42]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[43]  J. Stamler,et al.  Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. , 1986, Journal of the American College of Cardiology.

[44]  S. Houle,et al.  Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation. Results of a prospective randomized controlled trial using aspirin and dipyridamole in humans. , 1985, Journal of neurosurgery.

[45]  P. Sørensen,et al.  Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. , 1983, Stroke.

[46]  P. Touboul,et al.  "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. , 1983, Stroke.

[47]  G. Landi,et al.  A randomized trial of aspirin and sulfinpyrazone in patients with TIA. , 1982, Stroke.

[48]  Norman E. Breslow,et al.  Odds ratio estimators when the data are sparse , 1981 .

[49]  V. Matera,et al.  A randomized clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks (TIA). A one year follow-up. , 1981, La Ricerca in clinica e in laboratorio.

[50]  J. Stamler.  Aspirin in coronary heart disease , 1980 .

[51]  P. Elwood,et al.  ASPIRIN AND SECONDARY MORTALITY AFTER MYOCARDIAL INFARCTION , 1979, The Lancet.

[52]  W. S. Fields,et al.  Controlled Trial of Aspirin in Cerebral Ischemia. Part II: Surgical Group , 1978, Stroke.

[53]  R. Hardy,et al.  Controlled Trial of Aspirin in Cerebral Ischemia , 1977, Stroke.